Comparison of four commercial viral load techniques in an area of non-B HIV-1 subtypes circulation

被引:9
|
作者
Ndiaye, Ousseynou [1 ]
Diop-Ndiaye, Halimatou [1 ]
Ouedraogo, Abdou Salam [2 ]
Fall-Malick, Fatim Zahra [1 ]
Sow-Sall, Amina [1 ]
Thiam, Moussa [1 ]
Diouara, Abou Abadallah Malick [1 ]
Ndour, Cheikh Tidiane [1 ]
Gaye-Diallo, Aissatou [1 ]
Mboup, Souleymane [1 ]
Toure-Kane, Coumba [1 ]
机构
[1] Univ Cheikh Anta Diop Dakar, Lab Bacteriol Virol, CHU A Dantec, Dakar, Senegal
[2] Univ Ouagadougou, CHU Souro Sanou, Serv Bacteriol Virol, Bobo Dioulasso, Burkina Faso
关键词
HIV-1; Viral load; Comparison; GENETIC DIVERSITY; RNA QUANTITATION; MONITOR V1.5; TAQMAN HIV-1; ASSAYS; PERFORMANCE; AMPLICOR; FAILURE; RESISTANCE; INFECTION;
D O I
10.1016/j.jviromet.2015.06.002
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this study was to compare four HIV-1 viral quantitation platforms, Nuclisens EasyQ v2.0 (R) (EQ), COBAS AmpliPreP/Cobas Tagman (R) HIV-1 test v 2.0 (CTM), GENERIC HIV CHARGE VIRALE (R) (GEN), with Abbott Real Time HIV-1 (R) (m2000sp/rt) as reference technique. The study had first evaluated m2000sp/rt performances and then compared quantitation between techniques. Discordant samples were genotyped on gag and pal gene and sequences were analyzed using Sequence locator and SeqPublish to detect eventual mismatches. Performance analysis of m2000sp/rt showed good results with coefficients of variation values (CV) of 1.35%, 0.65%, and 0.54% for repeatability testing of low, intermediate and high concentrations, respectively. Reproducibility tests showed low CV values with 2.36% and 1.42% for low and high concentration levels, respectively and contamination test was very low value with 0.94%. Correlation and concordance between techniques ranged from r(2) = 0.98 and bias = -0.00185 (for m2000sp/rt vs CTM) to r(2) = -0.90 and bias = -0.135 (for EQ vs GEN). Discrepancies were observed on 37 samples mostly CRF02_AG but despite some mismatches, sequence analysis (26/37) did not show any remarkable differences between CRF02_AG queries and references. This study showed good correlation and good concordance between techniques. However, EQ yielded under-quantitation of CRF02_AG. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:122 / 131
页数:10
相关论文
共 50 条
  • [31] Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Naive Patients Infected with HIV-1 B and Non-B Subtypes
    Stuermer, Martin
    Stephan, Christoph
    Gute, Peter
    Knecht, Gaby
    Bickel, Markus
    Brodt, Hans-Reinhard
    Doerr, Hans W.
    Guertler, Lutz
    Lecocq, Pierre
    van Houtte, Margriet
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) : 5362 - 5366
  • [32] Characterization of HIV-1 non-B subtypes prevalent in a population attending a London HIV/AIDS outpatients clinic
    van Hooff, F
    Loveday, C
    Burke, A
    Johnson, M
    AIDS, 2000, 14 : S109 - S109
  • [33] Viral load differences in early infection with two HIV-1 subtypes
    Hu, DJ
    Vanichseni, S
    Mastro, TD
    Raktham, S
    Young, NL
    Mock, PA
    Subbarao, S
    Parekh, BS
    Srisuwanvilai, L
    Sutthent, R
    Wasi, C
    Heneine, W
    Choopanya, K
    AIDS, 2001, 15 (06) : 683 - 691
  • [34] Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes
    Fofana, Djeneba B.
    Charpentier, Charlotte
    Maiga, Almoustapha I.
    Lambert-Niclot, Sidonie
    Sayon, Sophie
    Desire, Nathalie
    Simon, Anne
    Yazdanpanah, Yazdan
    Katlama, Christine
    Descamps, Diane
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Soulie, Cathia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 130 - 135
  • [35] Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes
    Fofana, D. B.
    Charpentier, C.
    Maiga, A. I.
    Lambert-Niclot, S.
    Sayon, S.
    Simon, A.
    Katlama, C.
    Yazdanpanah, Y.
    Descamps, D.
    Calvez, V.
    Marcelin, A. G.
    Soulie, C.
    ANTIVIRAL THERAPY, 2014, 19 : A114 - A114
  • [36] Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes
    Charpentier, Charlotte
    Lambert-Niclot, Sidonie
    Alteri, Claudia
    Storto, Alexandre
    Flandre, Philippe
    Svicher, Valentina
    Perno, Federico
    Brun-Vezinet, Francoise
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Ceccherini-Silberstein, Francesca
    Descamps, Diane
    PLOS ONE, 2013, 8 (01):
  • [37] Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B
    Scherrer, Alexandra U.
    Ledergerber, Bruno
    von Wyl, Viktor
    Boeni, Juerg
    Yerly, Sabine
    Klimkait, Thomas
    Buergisser, Philippe
    Rauch, Andri
    Hirschel, Bernard
    Cavassini, Matthias
    Elzi, Luigia
    Vernazza, Pietro L.
    Bernasconi, Enos
    Held, Leonhard
    Guenthard, Huldrych F.
    CLINICAL INFECTIOUS DISEASES, 2011, 53 (11) : 1143 - 1152
  • [38] Characteristics of antiretroviral treatment-naive patients with HIV-1 B and non-B subtypes in western Sydney
    Varma, R.
    Sawleshwarkar, S.
    Herring, B.
    Wong, A.
    Thappa, K.
    Couldwell, D.
    Dominic, D.
    HIV MEDICINE, 2014, 15 : 87 - 88
  • [39] In vitro selection of novel etravirine-associated resistance mutations in B and non-B HIV-1 subtypes
    Asahchop, E. L.
    Tremblay, C. L.
    Brenner, B. G.
    Oliveira, M.
    Moisi, D.
    Toni, T.
    Spira, B.
    Wainberg, M. A.
    ANTIVIRAL THERAPY, 2010, 15 : A134 - A134
  • [40] Detection of HIV-1 Group M non-B subtypes and HIV-1 Group O specimens with a modified recombinant HIV-1/HIV-2 enzyme immunoassay
    Stephens, JE
    Falcon, B
    Gallarda, J
    Motley, C
    Newton, J
    Peterson, MB
    Skora, C
    Devare, S
    Vallari, A
    Brennan, C
    Swanson, P
    TRANSFUSION, 1997, 37 (09) : S179 - S179